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ABBREVIATIONS 37 
ART: Arterial revascularization trial  38 
BITA: Bilateral internal thoracic arteries 39 
BMI: Body mass index  40 
CABG: coronary artery bypass grafting  41 
CVA: cerebrovascular accident  42 
COPD: chronic obstructive pulmonary disease 43 
ITA: internal thoracic artery  44 
LVEF: left ventricular ejection fraction  45 
MACCE: major cardiac and cerebrovascular events 46 
MI: myocardial infarction 47 
PCI: percutaneous coronary intervention  48 
POAF: postoperative atrial fibrillation  49 
PS: propensity score 50 
SITA: Single internal thoracic artery  51 
SVG: saphenous vein grafts  52 
SMD: standardized mean difference   53 
Central Message: The incidence of intraoperative bilateral internal thoracic artery (BITA) 54 
graft conversion in the ART was not irrelevant despite participating surgeons were requested 55 
to have expertise in BITA grafts.  56 
 57 
Prospective statement: Reasons beyond bilateral internal thoracic artery (BITA) grafts 58 
underutilization remain unclear. In the ART participating surgeons were requested to have 59 
expertise in BITA grafts. We found that in the ART the incidence of intraoperative BITA graft 60 
conversion was not irrelevant thus supporting that BITA grafts may represent a challenge also 61 
for experienced surgeons.  62 
  63 
Abstract 64 
Background: The arterial revascularization trial (ART) has been designed to answer the 65 
question whether the use of bilateral internal thoracic arteries (BITA) can improve 10-year 66 
outcomes when compared to single internal thoracic artery (SITA). In the ART, a significant 67 
proportion of patients initially allocated to BITA received other conduit strategies. We sought 68 
to investigate the incidence and clinical implication of BITA grafts conversion in the ART. 69 
Methods: Among patients enrolled in the ART (n=3102), we excluded those allocated to SITA 70 
(n=1554), those who did not undergo surgery (n=16) and those operated on but withdrew after 71 
randomization (n=7). Propensity score matching was used to compare converted vs non-72 
converted BITA groups. 73 
Results: A total of 1525 patients were operated with intention to receive BITA grafting. Of 74 
those, 233 (15.3%) were converted to other conduit selection strategies. Incidence of 75 
conversion largely varied across 28 centres involved (from 0% to 42.9%). The most common 76 
reason for BITA grafts conversion was the evidence of at least one internal thoracic artery not 77 
suitable which was reported in 77 cases. Patients with intraoperative BITA graft conversion 78 
received a lower number of grafts (2.95±0.84 vs 3.21±0.74; P<0.001). However, hospital 79 
mortality rate was comparable to those who did not require BITA graft conversion (0 vs 1.6%; 80 
P=0.1) as well as the incidence of major complications. At 5 years we found a non-significant 81 
excess of deaths (11.9% vs 8.4%; P=0.1) and major adverse events (17.1% 13.2%; P=0.1) 82 
mainly driven by an excess of revascularization in patients requiring conversion.  83 
Conclusions: The incidence of intraoperative BITA graft conversion is not irrelevant . BITA 84 
graft conversion is not associated with increased operative morbidity but its effect on late 85 
outcomes remain uncertain.   86 
Keywords: bilateral internal thoracic artery; randomised controlled trial; outcomes  87 
Despite evidence from large observational studies have consistently suggested that the use of 88 
bilateral internal thoracic artery (BITA) graft improves long term survival when compared to 89 
single internal thoracic artery (SITA) graft in coronary artery bypass graft (CABG) surgery 90 
[1,2], the use of BITA graft remains particularly low. As a matter of fact, BITA grafting 91 
represents only 4–12% of all CABG procedures over the more traditional use of the SITA with 92 
additional saphenous vein grafts (SVG) [3]. Reasons for BITA underutilization are 93 
multifactorial. Most of surgeons just do not perform BITA grafting based on the increased risk 94 
of sternal wound complications and technical complexity [4,5]. However, same patients 95 
initially intended to receive BITA grafts requires intraoperative conversion to other conduits 96 
strategies. Incidence and causes of intraoperative BITA grafts conversion and its clinical 97 
implication has never been investigated.  98 
The arterial revascularization trial (ART) has been designed to answer the question whether 99 
the use of bilateral internal thoracic arteries (BITA) can improve 10-year outcomes when 100 
compared to single internal thoracic artery (SITA) in coronary artery bypass grafting (CABG) 101 
[6]. Interim 5-year results have shown similar clinical outcomes between the two groups [7]. 102 
In ART only surgeons with experience of ≥50 BITA operations were able to undertake BITA 103 
procedures in the trial [6]. We sought to investigate reasons for intraoperative BITA grafts 104 
conversion and its clinical implication by performing a post-hoc analysis of the ART.    105 
Methods  106 
A post-hoc analysis of 5-year outcomes of the ART trial was conducted. This research adheres 107 
to the principles set forth in the Declaration of Helsinki 108 
(http://www.wma.net/en/30publications/10policies/b3/index.html). Among patients enrolled 109 
in the ART (n=3102) from 2004 to 2007, we excluded those allocated to SITA (n=1554) and 110 
those who did not undergo surgery (n=16) and those operated on but withdrew after 111 
randomization (n=7).  112 
Trial design 113 
The ART was approved by the institutional review board of all participating centers, and 114 
informed consent was obtained from each participant. The protocol for the ART has been 115 
published [6]. Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 116 
hospitals in 7 countries, with patients being randomized equally to SITA or BITA grafts. 117 
Eligible patients were those with multivessel coronary artery disease undergoing CABG. BITA 118 
grafts configuration (y graft vs. in-situ graft vs. free graft) was left at discretion of the surgeon 119 
(video). Patients requiring single grafts or redo CABG were excluded. Patients with evolving 120 
MI (defined as the rise and fall of a biomarker together with one of a longer list of criteria 121 
comprising ischaemic symptoms, the development of pathologic Q waves, ischaemic ECG 122 
changes, and a coronary artery intervention) were also excluded. However, patients with 123 
unstable angina defined as pain on any activity or rest pain were included.  124 
Follow-up  125 
Questionnaires were sent to study participants by post every year after surgery. No clinic visits 126 
were planned apart from the routine clinical 6-week post-operative visit. Participants were sent 127 
stamped addressed envelopes to improve the return rates of postal questionnaires. Study co-128 
ordinators contacted participants by telephone to alert them to the questionnaire’s arrival and 129 
to ask them about medications, adverse events and health services resource use. Five-year 130 
follow-up was completed for all patients included in the present analysis.   131 
Study outcomes 132 
Hospital outcomes investigated were re-exploration for bleeding, intra-aortic balloon pump 133 
(IABP) insertion, myocardial infarction (MI), cerebrovascular accident (CVA), postoperative 134 
atrial fibrillation (POAF), sternal complications revascularization and hospital mortality.  Late 135 
outcomes were 5-year all-cause mortality and cumulative incidence of major cardiac and 136 
cerebrovascular events (MACCE) including cardiovascular (CV) death, CVA, MI and repeat 137 
revascularization.  138 
Outcomes definitions 139 
Death was classified into cardiovascular and non-cardiovascular, where possible, using autopsy 140 
reports and death certificates. Congestive heart failure, arrhythmia or myocardial infarction, 141 
pulmonary embolus and dissection were considered cardiovascular causes of death.  142 
MI was diagnosed when two of the following three criteria were present: 1. Unequivocal ECG 143 
changes; 2. Elevation of cardiac enzyme(s) above twice the upper limit of normal or diagnostic 144 
troponin rises; 3. Chest pain typical for acute MI which lasted more than 20 minutes.  CVA 145 
was defined as new neurological deficit evidenced by clinical signs of paresis, plegia or new 146 
cognitive dysfunction including any mental status alteration lasting more than 24 hours and/or 147 
evidence on CT or MRI scan of recent brain infarct (less than 6 months). Repeat 148 
revascularization was defined as coronary bypass surgery or percutaneous coronary 149 
intervention (PCI) performed after trial procedure. Sternal complications included sternal 150 
wound infection requiring antibiotics, VAC therapy, debridement or reconstruction.  151 
Statistical analysis  152 
Multiple imputation (m=3) was used to address missing data. Rubin’s method [8] was used to 153 
combine results from each of the imputed data sets (Amelia R package). Due to lack of 154 
randomization with regards to BITA conversion, a propensity score (PS) was generated for 155 
each patient from a multivariable logistic regression model (C-statistics 0.64) based on pre-156 
specified set of covariates (as listed in Table 1) with requiring conversion vs non-converted as 157 
a binary dependent variable [9]. Pairs of patients were derived using greedy 1:3 matching with 158 
a calliper of width of 0.2 standard deviation of the logit of the PS (nonrandom R package). The 159 
quality of the match was assessed by comparing selected pre-treatment variables in propensity 160 
score–matched patients using the standardized mean difference (SMD), with an absolute 161 
standardized difference of greater than 10% taken to represent meaningful covariate imbalance. 162 
[9]. McNemar's test and paired t-test was used to assess the statistical significance of the risk 163 
difference for hospital outcomes and stratified log-rank was used to assess the statistical 164 
significance of the risk difference for mortality and MACCE at 5 years. Risk competing 165 
framework was used to estimate the treatment effect on MACCE individual components 166 
(survival R package and riskRegression R package). All p-values <0.05 were considered to 167 
indicate statistical significance.  168 
Results 169 
Study population  170 
A total of 1525 patients were operated with intention to receive BITA grafting. Of those, 233 171 
(15.3%) were converted to other conduit selection strategies. Incidence of conversion largely 172 
varied across 131 participating surgeons (Figure 1 and Supplementary Table 1). The most 173 
common reason for BITA grafts conversion was the evidence of at least one internal thoracic 174 
artery (ITA) not suitable which was reported in 77 (33.0%) cases. This was due to during 175 
harvesting (n=41), poor flow without apparent injury (n=23) and conduit too short for grafting 176 
(n=13).  The second most common reasons for BITA conversion were poor target not suitable 177 
for BITA grafts in 44 cases (18.9%) and perceived increased risk for sternum complication (i.e. 178 
osteoporosis) in 38 cases (16.3%). Other causes were hemodynamic instability which occurred 179 
during BITA harvesting in 19 cases (8.1%), intraoperative evidence of other cardiac 180 
pathologies requiring intervention in 6 (2.6%) cases and time constrain in 6 (2.6%) cases. In 181 
43 cases (18.5%), surgeons decided to not perform BITA grafts without providing a 182 
justification (Central Picture).      183 
Baseline characteristics in the two groups are reported in Table 1. Overall subjects with 184 
intraoperative BITA graft conversion presented a higher risk profile. In particular they were 185 
more likely to be older and female and were more likely to have diabetes, chronic obstructive 186 
pulmonary disease (COPD) and left ventricular ejection fraction (LVEF)<0.5. Intraoperative 187 
data breakdown according to causes of BITA conversion showed that increased body mass 188 
index (BMI) and diabetes was more common among those converted as perceived at higher 189 
risk for risk infection, female gender was more common among those with poor targets and 190 
reduced LVEF was more common among those with those with hemodynamic instability 191 
during ITA harvesting (Supplementary Table 3). After matching the two groups were 192 
comparable for all baseline risk factors (all SMD<0.10; Figure 2).  193 
Intra-operative data 194 
Intraoperative data are summarized in Table 2. Patients who had BITA graft conversion were 195 
more likely to be undergo on-pump surgery (23.2% vs. 42.1%) and to receive a lower number 196 
of grafts (2.95±0.84 vs 3.21±0.74), with LAD (95.3% vs 99.1%) and circumflex (82% vs 197 
95.9%) territories being more likely to remain ungrafted. In the BITA conversion group, 19 198 
(8.2%) patients received SVG only. Intraoperative data breakdown according to causes of 199 
BITA conversion showed that the number of grafts was lower among those found to have poor 200 
targets (2.52±0.90), and the rate of patients receiving SVG only was higher among those with 201 
unsuitable ITA (18.2%) or hemodynamic instability during harvesting (15.8%) 202 
(Supplementary Table 4).  203 
Outcomes 204 
Hospital outcomes are summarised in Table 3. Overall patients requiring BITA graft 205 
conversion was not associated with a higher incidence of hospital morbidity or mortality. In 206 
particular, no patient requiring BITA graft conversion experienced hospital death and the need 207 
for intra-aortic balloon pump and need for repeat revascularization was comparable between 208 
the two groups. Hospital breakdown according to causes of BITA conversion showed that those 209 
requiring conversion for hemodynamic instability during ITA harvesting presented the highest 210 
rate of IABP insertion, renal replacement therapy and postoperative MI (Supplementary Table 211 
5).  212 
Five-year outcomes are summarised in Table 4 and Figure 3. In patients requiring conversion 213 
we found a non-significant excess of deaths (11.9% vs 8.4%; P=0.1) and MACCE (17.1% 214 
13.2%; P=0.1) mainly driven by an excess of revascularization (Figure 4). Those who required 215 
conversion for hemodynamic instability during ITA harvesting and found to have poor target 216 
or unsuitable ITA tended to have a higher rate of mortality and MACCE. (Supplementary Table 217 
5).  218 
Conduit selection in patients initially allocated to SITA 219 
For descriptive purpose, we also reported conduits selection in those initially allocated to SITA 220 
graft. Among 1554 patients initially allocated to SITA, eight were not operated on (1 death, 4 221 
withdrew, 3 cases with no reason reported) and the remaining 1546 underwent surgery. Of 222 
those, 1494 received SITA graft (96.7%) and 38 received BITA grafts (2.5%) for the following 223 
reasons: no other suitable conduit available (n=21, 1.4%), withdrew (n=2, 0.1%) and reason 224 
not report (n=15, 1.0%). Only 14 patients received neither SITA nor BITA (0.9%) for the 225 
following reasons: ITA unsuitable (n=10, 0.6%), unsuitable target (n=2, 0.1%), hemodynamic 226 
instability (n=1, 0.5%), need for unplanned surgery (n=1, 0.5%).   227 
Discussion 228 
Reasons beyond underutilization of the BITA graft remains uncertain [4,5]. Many surgeons 229 
just do not perform BITA grafts in view of the increased risk of sternal wound [10] and 230 
technical complexity [4]. However, the incidence of intraoperative BITA grafts conversion to 231 
other graft strategies in patients initially intended to receive BITA grafts remains unknown [7]. 232 
The perceived increased risk of operative morbidity related to intraoperative conversion can 233 
partially contribute to the reluctance of many surgeons to perform BITA grafts also in view of 234 
the current intense professional and public scrutiny of cardiac surgeons’.  235 
The ART trial represents a unique opportunity to investigate the incidence and causes of 236 
intraoperative BITA graft conversion [7]. Interestingly, despite participating surgeons were 237 
anticipated to be expert in BITA grafts, the rate of intraoperative conversion was not irrelevant. 238 
In fact 15.3% of patients initially intended to received BITA grafts required intraoperative 239 
conversion to other conduit strategies. However, we noticed that there was a very large 240 
variation in BITA grafting conversion across centres and surgeons which supports the central 241 
role for individual surgeon experience. Interestingly, unsuitable ITA was reported as the main 242 
reason (33%) for intraoperative BITA grafts conversion to other conduit strategies and it was 243 
mainly related to injury during harvesting. Of notice, the rate of unsuitable ITA in those 244 
allocated to SITA graft was only 0.6% suggesting that harvesting two ITAs is more demanding 245 
and can influence surgeon’s precisions. In addition, in 44 patients, BITA was not performed 246 
because of poor target. Among those patients, only 7 patients requited 1 grafts only. In all other 247 
cases, SVG and/or RA were used in addition to SITA grafts, suggesting that technical difficulty 248 
of performing BITA grafts rather than the absence of graftable targets. We also found that 19 249 
patients become unstable during BITA harvesting and we can hypothesis that prolonged heart 250 
compression secondary to the use of chest retractor during ITA harvesting may not be always 251 
tolerated especially in presence of reduced LVEF. On the other hand, a main reason for 252 
conversion not related to complication or technical complexity was the perception of increased 253 
risk of sternal wound complication after chest opening (i.e. osteoporotic sternum). In case of 254 
intraoperative conversion, SITA plus SVG was the most commonly opted strategy followed by 255 
SITA plus RA. Of note, 19 patients (8.2%) received SVG only.  256 
In contrast to other clinical scenarios when intraoperative conversion significantly increases 257 
operative morbidity and mortality such as off-pump to on-pump conversion [11], BITA grafts 258 
conversion was not associated with significantly higher rate of operative complications 259 
although those requiring conversion for hemodynamic instability during ITA harvesting 260 
presented a numerically higher rate of IABP insertion, renal replacement therapy and 261 
postoperative MI. At 5 years, we found a non-significant trend towards an excess of death and 262 
MACCE in patients requiring intraoperative conversion in particular among those with 263 
perioperative hemodynamic instability, poor target and unsuitable ITA. We can speculate that 264 
perioperative myocardial injury, lower number of grafts and excess of SVG only strategy in 265 
these three groups respectively might have partially contributed to this trend. 266 
The unique technical challenges of BITA grafts fuels the perception that adoption of this 267 
myocardial revascularization strategy may increase operative morbidity in particular when 268 
intraoperative conversion to other conduit strategies is required. The present results support the 269 
hypothesis that BITA conversion does not significantly increase operative morbidity. However, 270 
the large variation in BITA conversion and its potential implication on late outcomes highlight 271 
the importance of negotiating the learning curve with appropriate patient selection, 272 
individualized grafting strategy, peer-to-peer training of the entire team, and graded clinical 273 
experience.  274 
There are two main limitations in the present analysis. This is a retrospective analysis of the 275 
ART and we cannot exclude residual confounding factors between the two groups despite 276 
propensity score adjustment. The number of patients requiring conversion was relatively small 277 
and there was a relatively low incidence of adverse events. Therefore, the analysis was likely 278 
to be underpowered to detect significant difference between groups for comparisons. Finally, 279 
we had no information whether BITA injury during harvesting occurred with skeletonised or 280 
pedicled technique.  281 
In conclusion, the incidence of intraoperative BITA graft conversion is not irrelevant also 282 
among experienced surgeons participating in ART. While intraoperative BITA grafts 283 
conversion does not increase the risk of operative mortality and major complications, BITA 284 
conversion might be associated with poorer outcomes at long term follow-up. However, the 285 
latter conclusions require further investigations.    286 
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  358 
Table 1. Baseline characteristics 359 
SMD: standardized mean difference; PSM: propensity score matching; BMI: body mass index; 360 
SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive 361 
pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA: 362 
cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous coronary intervention; 363 
AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease.  364 
  365 
  Requiring 
Conversion 
Not  
Converted 
Before PSM 
SMD 
before 
PSM 
Not converted 
matched 
SMD 
after PSM 
N 233 1292  699  
Age (mean (sd)) 65 (9) 63 (9) 0.229 65 (8) 0.019 
Female = 1 (\%) 47 (20.2) 176 (13.6) 0.175 135 (19.3) 0.022 
BMI (mean (sd)) 29 (4) 28 (4) 0.117 29 (4) 0.005 
SBP (mean (sd)) 132 (18) 132 (18) 0.003 132 (18) 0.015 
DBP (mean (sd)) 75 (11) 75 (11) 0.011 75 (11) 0.016 
Creatinine (mmol/L)  95 (21) 97 (21.5) 0.061 96 (21) 0.015 
NYHA III/IV n(%) 42 (18.0) 290 (22.4) 0.110 131 (18.7) 0.018 
Unstable angina n(%) 14 (6.0) 102 (7.9) 0.074 43 (6.2) 0.006 
Treated Hypertension  177 (76.0) 1002 (77.6) 0.038 543 (77.7) 0.041 
Treated Hyperlipaemia  222 (95.3) 1216 (94.1) 0.052 663 (94.8) 0.020 
Diabetes n(%)   0.140  0.046 
No 165 (70.8) 994 (76.9)  508 (72.7)  
On insulin 17 ( 7.3) 76 ( 5.9)  51 ( 7.3)  
Oral 51 (21.9) 222 (17.2)  140 (20.0)  
Smoking n(%)   0.046  0.032 
Current 32 (13.7) 198 (15.3)  92 (13.2)  
Ex 129 (55.4) 696 (53.9)  381 (54.5)  
Never 72 (30.9) 398 (30.8)  226 (32.3)  
COPD n(%) 13 (5.6) 29 (2.2) 0.173 26 (3.7) 0.088 
Asthma n(%) 11 (4.7) 67 (5.2) 0.021 32 (4.6) 0.007 
PVD n(%) 17 (7.3) 85 (6.6) 0.028 49 (7.0) 0.011 
TIA n(%) 8 (3.4) 42 (3.3) 0.010 19 (2.7) 0.041 
CVA n(%) 5 (2.1) 37 (2.9) 0.046 12 (1.7) 0.031 
MI n(%) 104 (44.6) 506 (39.2) 0.111 322 (46.1) 0.029 
PCI n(%) 40 (17.2) 198 (15.3) 0.050 117 (16.7) 0.011 
Preop AF pre n(%) 4 (1.7) 15 (1.2) 0.047 11 (1.6) 0.011 
LVEF\_pre (\%)   0.187  0.033 
≥ 50% (good) 161 (69.1) 994 (76.9)  473 (67.7)  
31-49% (moderate) 67 (28.8) 268 (20.7)  209 (29.9)  
≤ 30% (poor) 5 (2.1) 30 (2.3)  17 (2.4)  
LMD  n(%) 40 (17.2) 282 (21.8) 0.118 127 (18.2) 0.026 
Table 2. Intraoperative data 366 
 Requiring 
Conversion 
Not  
Converted 
Before PSM 
P-value 
Before 
PSM 
Not converted 
matched 
P-value 
After PSM 
n 233 1292  699  
Off-pump  n(%) 54 (23.2) 584 (45.2) <0.001 294 (42.1) <0.001 
LAD  n(%) 222 (95.3) 1278 (98.9) <0.001 693 (99.1) <0.001 
Circumflex  n(%) 191 (82.0) 1231 (95.3) <0.001 670 (95.9) <0.001 
RCA  n(%) 157 (67.4) 890 (68.9) 0.705 488 (69.8) 0.539 
Diagonal branches  n(%) 64 (27.5) 395 (30.6) 0.382 206 (29.5) 0.617 
N grafts (mean (sd)) 2.95 (0.84) 3.21 (0.77) <0.001 3.21 (0.74) <0.001 
Conduits (%)   <0.001  <0.001 
     Unknown  0 ( 0.0) 2 ( 0.2)  0 ( 0.0)  
     BITA  270 (20.9)  139 (19.9)  
     BITA+RA  215 (16.6)  115 (16.5)  
     BITA+RA+SV  44 ( 3.4)  23 ( 3.3)  
     BITA+SV  761 (58.9)  422 (60.4)  
     LITA 7 ( 3.0)     
     LITA+RA 22 ( 9.4)     
     LITA+RA+SV 12 ( 5.2)     
     LITA+SV 156 (67.0)     
     RA 1 ( 0.4)     
     RA+SV 2 ( 0.9)     
     RITA 3 ( 1.3)     
     RITA+RA 2 ( 0.9)     
     RITA+RA+SV 1 ( 0.4)     
     RITA+SV 8 ( 3.4)     
     SVG 19 ( 8.2)     
PSM: propensity score matching; LAD: left anterior descending artery; RCA: right coronary 367 
artery; BITA; bilateral internal thoracic arteries; RA: radial artery; SVG: saphenous vein graft   368 
Table 3. Hospital outcomes 369 
  Requiring 
Conversion 
Not  
Converted 
Before 
PSM 
P-value 
Before 
PSM 
Not  
converted 
matched 
P-value 
After 
PSM 
N 233 1292  699  
Re-exploration for bleeding n(%) 10 (4.3) 47 (3.6) 0.8 20 (2.9) 0.4 
IABP insertion n(%) 12 (5.2) 55 (4.3) 0.7 36 (5.2) 1 
Renal replacement therapy n(%) 6 (2.6) 85 (6.6) 0.03 52 (7.4) 0.01 
Sternal complications n(%) 13 (5.6) 64 (5.0) 0.8 36 (5.2) 0.9 
Death n(%) 0 (0.0) 17 (1.3) 0.2 11 (1.6) 0.1 
MI n(%) 7 (3.0) 18 (1.4) 0.1 12 (1.7) 0.4 
CVA n(%) 5 (2.1) 13 (1.0) 0.2 9 (1.3) 0.5 
Revascularization n(%) 1 (0.4) 9 (0.7) 1 5 (0.7) 1 
POAF n(%) 69 (29.6) 329 (25.5) 0.2 208 (29.8) 1 
PSM: propensity score matching; IABP: intra-aortic balloon pump; Myocardial infarction; 370 
CVA: cerebrovascular accident; POAF: postoperative atrial fibrillation  371 
Table 4. Five-year outcomes   372 
  Converted Not  
Converted 
Before PSM 
P-value 
Before 
PSM 
Not converted 
matched 
P-value 
N 233 1292  699  
Mortality at 5 years 27(11.9) 104(8.2) 0.08 58(8.4) 0.1 
MACCE at 5 years 39(17.1) 155(12.4) 0.03 90(13.2) 0.1 
cardiovascular death 8(3.5) 44(3.5) 1 29(4.2) 0.7 
MI 9(3.9) 42(3.3) 0.6 24(3.5) 0.7 
CVA 7(3.0) 31(2.4) 0.6 19(2.7) 0.8 
Revascularization 12(8.2) 81(6.4) 0.2 43(6.2) 0.2 
PSM: propensity score matching; MACCE: major adverse cardiac and cerebrovascular events; 373 
MI: myocardial infarction; CVA: cerebrovascular accident 374 
  375 
Figure Legend 376 
Central Picture: BITA grafts allocation and conversion in the ART (BITA: bilateral interval 377 
thoracic artery; SITA: single internal thoracic artery; ITA: internal thoracic artery) 378 
Figure 1. Scatter plot showing total number of cases initially allocated to BITA grafts 379 
performed by individual surgeons and relative rate of BITA conversion. 380 
Figure 2. Changes in standardized mean after matching (SMD: standardized mean difference; 381 
PSM: propensity score matching; BMI: body mass index; SBP: systolic blood pressure; DBP: 382 
diastolic blood pressure; COPD: chronic obstructive pulmonary disease; PVD: peripheral 383 
vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: 384 
myocardial infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation; 385 
LVEF: left ventricular ejection fraction; LMD: left main disease).  386 
Figure 3. Cumulative incidence of mortality and major adverse cardiac and cerebrovascular 387 
events (MACCE) in the matched sample 388 
Figure 4. Cumulative incidence of cardiovascular (CV) death, myocardial infarction (MI), 389 
cerebrovascular accident (CVA) and revascularization in the matched sample 390 
Video. Skeletonised left internal thoracic artery during off-pump surgery   391 
Supplementary Table 1. Number of cases performed initially allocated to bilateral interval 392 
thoracic artery (BITA) grafts and BITA conversion rate. 393 
#Surgeon 
Total number of 
cases performed 
initially allocated to 
BITA grafts 
%BITA grafts conversion 
Unknow 67 23.9% 
1 1 0.0% 
2 1 100.0% 
3 1 0.0% 
4 1 0.0% 
5 1 100.0% 
6 15 0.0% 
7 9 22.2% 
8 6 0.0% 
9 1 100.0% 
10 9 33.3% 
11 1 0.0% 
12 1 100.0% 
13 2 100.0% 
14 1 0.0% 
15 1 0.0% 
16 15 6.7% 
17 5 0.0% 
18 8 0.0% 
19 18 5.6% 
20 17 5.9% 
21 15 13.3% 
22 6 33.3% 
23 20 20.0% 
24 9 11.1% 
25 15 0.0% 
26 7 28.6% 
27 30 30.0% 
28 5 0.0% 
29 6 0.0% 
30 8 50.0% 
31 4 0.0% 
32 9 0.0% 
33 15 13.3% 
34 7 0.0% 
35 40 10.0% 
36 1 0.0% 
37 4 25.0% 
38 10 50.0% 
39 13 23.1% 
40 7 28.6% 
41 1 0.0% 
42 2 0.0% 
43 12 16.7% 
44 1 0.0% 
45 12 41.7% 
46 2 0.0% 
47 2 0.0% 
48 1 0.0% 
49 34 20.6% 
50 9 55.6% 
51 24 8.3% 
52 15 26.7% 
53 17 70.6% 
54 1 0.0% 
55 5 0.0% 
56 1 0.0% 
57 29 20.7% 
58 8 25.0% 
59 1 0.0% 
60 4 25.0% 
61 7 42.9% 
62 3 0.0% 
63 1 0.0% 
64 5 0.0% 
65 8 37.5% 
66 12 16.7% 
67 2 50.0% 
68 17 23.5% 
69 28 3.6% 
70 14 21.4% 
71 1 100.0% 
72 4 0.0% 
73 2 0.0% 
74 29 10.3% 
75 41 0.0% 
76 18 38.9% 
77 22 31.8% 
78 4 25.0% 
79 3 100.0% 
80 1 0.0% 
81 33 6.1% 
82 4 0.0% 
83 1 0.0% 
84 9 0.0% 
85 1 0.0% 
86 16 0.0% 
87 1 0.0% 
88 1 0.0% 
89 2 50.0% 
90 16 6.3% 
91 11 54.5% 
92 19 21.1% 
93 3 33.3% 
94 19 42.1% 
95 1 100.0% 
96 4 0.0% 
97 1 100.0% 
98 1 0.0% 
99 18 5.6% 
100 22 13.6% 
101 2 0.0% 
102 2 0.0% 
103 8 0.0% 
104 33 0.0% 
105 1 0.0% 
106 12 16.7% 
107 12 8.3% 
108 3 0.0% 
109 4 100.0% 
110 1 0.0% 
111 2 100.0% 
112 22 18.2% 
113 4 0.0% 
114 10 10.0% 
115 2 0.0% 
116 2 0.0% 
117 1 0.0% 
118 211 1.9% 
119 1 0.0% 
120 16 25.0% 
121 1 0.0% 
122 15 33.3% 
123 8 0.0% 
124 3 0.0% 
125 1 100.0% 
126 11 9.1% 
127 3 0.0% 
128 1 0.0% 
129 33 15.2% 
130 99 13.1% 
131 3 33.3% 
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Supplementary Table 2. Baseline characteristics according to cause of bilateral interval thoracic artery (BITA) grafts conversion   
 High risk for 
sternal 
complication 
At least 1  
ITA not  
suitable 
Target  
not suitable 
Other  
cardiac 
pathologies 
Justification  
not provided 
Time 
constrain 
Unstable 
during ITA 
harvesting 
N 38 77 44 6 43 6 19 
Age (mean (sd)) 65.01 (8.87) 65.59 (8.19) 65.64 (9.39) 68.88 (8.63) 64.43 (8.63) 64.44 (8.29) 65.76 (8.68) 
Female n(%) 7 (18.4) 16 (20.8) 12 (27.3) 0 (0.0) 10 (23.3) 0 (0.0) 2 (10.5) 
BMI (mean (sd)) 30.21 (4.28) 27.51 (3.25) 28.82 (3.11) 27.91 (2.60) 29.53 (4.01) 29.10 (2.85) 28.54 (4.61) 
SBP (mean (sd)) 132 (15) 131 (20) 134 (19) 129 (15) 130 (16) 140 (12) 131 (17) 
DBP (mean (sd)) 78 (10) 74 (10) 75 (10) 81 (11) 74 (13) 80 (15) 74 (10) 
Creatinine (mmol/L)  97.49 (23.50) 94.27 (18.31) 99.48 (25.05) 100.08 (25.67) 92.51 (18.37) 89.00 (11.47) 93.85 (20.55) 
NYHA III/IV n(%) 4 (10.5) 17 (22.1) 6 (13.6) 2 (33.3) 8 (18.6) 2 (33.3) 3 (15.8) 
Unstable angina n(%) 1 (2.6) 6 (7.8) 3 (6.8) 1 (16.7) 1 (2.3) 0 (0.0) 2 (10.5) 
Treated Hypertension  29 (76.3) 53 (68.8) 33 (75.0) 6 (100.0) 32 (74.4) 6 (100.0) 18 (94.7) 
Treated Hyperlipaemia  38 (100.0) 73 (94.8) 42 (95.5) 6 (100.0) 39 (90.7) 6 (100.0) 18 (94.7) 
Diabetes n(%)        
No 24 (63.2) 56 (72.7) 30 (68.2) 4 (66.7) 29 (67.4) 4 (66.7) 18 (94.7) 
On insulin 3 (7.9) 9 (11.7) 2 (4.5) 0 (0.0) 3 (7.0) 0 (0.0) 0 (0.0) 
Oral 11 (28.9) 12 (15.6) 12 (27.3) 2 (33.3) 11 (25.6) 2 (33.3) 1 (5.3) 
Smoking n(%)        
Current 6 (15.8) 7 (9.1) 7 (15.9) 1 (16.7) 7 (16.3) 1 (16.7) 3 (15.8) 
Ex 18 (47.4) 46 (59.7) 24 (54.5) 2 (33.3) 22 (51.2) 4 (66.7) 13 (68.4) 
Never 14 (36.8) 24 (31.2) 13 (29.5) 3 (50.0) 14 (32.6) 1 (16.7) 3 (15.8) 
COPD n(%) 3 (7.9) 4 (5.2) 1 (2.3) 0 (0.0) 4 (9.3) 0 (0.0) 1 (5.3) 
Asthma n(%) 3 (7.9) 1 (1.3) 0 (0.0) 1 (16.7) 6 (14.0) 0 (0.0) 0 (0.0) 
PVD n(%) 4 (10.5) 5 (6.5) 1 (2.3) 1 (16.7) 4 (9.3) 0 (0.0) 2 (10.5) 
TIA n(%) 2 (5.3) 3 (3.9) 3 (6.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
CVA n(%) 1 (2.6) 1 (1.3) 1 (2.3) 1 (16.7) 0 (0.0) 0 (0.0) 1 (5.3) 
MI n(%) 13 (34.2) 38 (49.4) 21 (47.7) 2 (33.3) 21 (48.8) 2 (33.3) 7 (36.8) 
PCI n(%) 14 (36.8) 10 (13.0) 9 (20.5) 1 (16.7) 2 (4.7) 0 (0.0) 4 (21.1) 
Preop AF pre n(%) 2 (5.3) 1 (1.3) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0) 0 (0.0) 
LVEF\_pre (\%)        
≥ 50% (good) 31 (81.6) 52 (67.5) 30 (68.2) 3 (50.0) 31 (72.1) 4 (66.7) 10 (52.6) 
31-49% (moderate) 6 (15.8) 24 (31.2) 12 (27.3) 3 (50.0) 12 (27.9) 2 (33.3) 8 (42.1) 
≤ 30% (poor) 1 (2.6) 1 (1.3) 2 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.3) 
LMD  n(%) 7 (18.4) 14 (18.2) 7 (15.9) 1 (16.7) 5 (11.6) 3 (50.0) 3 (15.8) 
ITA: internal thoracic artery; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive 
pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; 
PCI: percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease.  
 
 
  
Supplementary Table 3. Operative data according to cause of bilateral interval thoracic artery (BITA) grafts conversion.  
  
High risk for 
sternal 
complication 
At least 1  
ITA not  
suitable 
Target  
not suitable 
Other  
cardiac 
pathologies 
Justification  
not provided 
Time 
constrain 
Unstable 
during ITA 
harvesting 
n 38 77 44 6 43 6 19 
Off-pump  n(%) 4 (10.5) 23 (29.9) 15 (34.1) 1 (16.7) 9 (20.9) 0 (0.0) 2 (10.5) 
LAD  n(%) 37 (97.4) 76 (98.7) 37 (84.1) 5 (83.3) 43 (100.0) 6 (100.0) 18 (94.7) 
Circumflex  n(%) 37 (97.4) 70 (90.9) 25 (56.8) 5 (83.3) 33 (76.7) 6 (100.0) 15 (78.9) 
RCA  n(%) 24 (63.2) 52 (67.5) 31 (70.5) 3 (50.0) 26 (60.5) 6 (100.0) 15 (78.9) 
Diagonal branches  n(%) 12 (31.6) 22 (28.6) 7 (15.9) 1 (16.7) 14 (32.6) 2 (33.3) 6 (31.6) 
N grafts (mean (sd)) 3.03 (0.79) 3.04 (0.77) 2.52 (0.90) 2.83 (1.47) 3.00 (0.82) 3.50 (0.55) 3.16 (0.76) 
Conduits (%)        
     LITA 0 ( 0.0) 0 ( 0.0) 4 ( 9.1) 1 (16.7) 2 (  4.7) 0 (  0.0) 0 ( 0.0) 
     LITA+RA 2 ( 5.3) 3 ( 3.9) 4 ( 9.1) 0 ( 0.0) 13 ( 30.2) 0 (  0.0) 0 ( 0.0) 
     LITA+RA+SV 5 (13.2) 1 ( 1.3) 1 ( 2.3) 0 ( 0.0) 4 (  9.3) 0 (  0.0) 1 ( 5.3) 
     LITA+SV 30 (78.9) 48 (62.3) 32 (72.7) 5 (83.3) 21 ( 48.8) 5 ( 83.3) 15 (78.9) 
     RA 0 ( 0.0) 0 ( 0.0) 1 ( 2.3) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RA+SV 0 ( 0.0) 2 ( 2.6) 0 ( 0.0) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RITA 0 ( 0.0) 1 ( 1.3) 2 ( 4.5) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RITA+RA 0 ( 0.0) 1 ( 1.3) 0 ( 0.0) 0 ( 0.0) 1 (  2.3) 0 (  0.0) 0 ( 0.0) 
     RITA+RA+SV 0 ( 0.0) 1 ( 1.3) 0 ( 0.0) 0 ( 0.0) 0 (  0.0) 0 (  0.0) 0 ( 0.0) 
     RITA+SV 0 ( 0.0) 6 ( 7.8) 0 ( 0.0) 0 ( 0.0) 1 (  2.3) 1 ( 16.7) 0 ( 0.0) 
     SVG 1 ( 2.6) 14 (18.2) 0 ( 0.0) 0 ( 0.0) 1 (  2.3) 0 (  0.0) 3 (15.8) 
ITA: internal thoracic artery; LAD: left anterior descending artery; RCA: right coronary artery; BITA; bilateral internal thoracic arteries; RA: 
radial artery; SVG: saphenous vein graft 
  
Supplementary Table 4. Hospital outcomes and 5-year mortality and major adverse cardiac and cerebrovascular events (MACCE) according to 
cause of bilateral interval thoracic artery (BITA) grafts conversion   
  
High risk for 
sternal 
complication 
ITA not suitable Target not 
suitable 
Other cardiac 
pathologies 
Justification 
not provided 
Time 
constrain 
Unstable 
during 
harvesting 
N 38 77 44 6 43 6 19 
Re-exploration for bleeding n(%) 0 (0.0) 2 (2.6) 2 (4.5) 0 (0.0) 6 (14.0) 0 (0.0) 0 ( 0.0) 
IABP insertion n(%) 3 (7.9) 3 (3.9) 1 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 5 (26.3) 
Renal replacement therapy n(%) 1 (2.6) 1 (1.3) 1 (2.3) 0 (0.0) 1 (2.3) 1 (16.7) 1 ( 5.3) 
Sternal complications  n(%) 3 (7.9) 2 (2.6) 2 (4.5) 1 (16.7) 4 (9.3) 0 (0.0) 1 ( 5.3) 
Death  n(%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 ( 0.0) 
MI  n(%) 0 (0.0) 4 (5.2) 1 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (10.5) 
CVA  n(%) 1 (2.6) 3 (3.9) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 ( 0.0) 
Revascularization n(%) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 ( 0.0) 
POAF  n(%) 12 (31.6) 21 (27.3) 13 (29.5) 4 (66.7) 10 (23.3) 2 (33.3) 7 (36.8) 
Mortality at 5 years 4 (10.5) 9(11.9) 6(13.8) 0(0) 6(14.1) 0(0) 2(10.8) 
MACCE at 5 years 3(8) 18(24) 8(18.3) 1(16.7) 4(9.7) 1(16.7) 4(21.1) 
ITA: internal thoracic artery; IABP: intra-aortic balloon pump; Myocardial infarction; CVA: cerebrovascular accident; POAF: postoperative 
atrial fibrillation; MACCE: major adverse cardiac and cerebrovascular events 
 
 
